Stocktoria
DBV Technologies S.A. DBVT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2012-03-29
DBV Technologies S.A. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.6M | $4.2M | $15.7M | $4.8M | $5.7M |
| R&D expense | $116.7M | $89.3M | $60.2M | $75.5M | $70.3M |
| Operating income | -$147.1M | -$116.6M | -$76.4M | -$96.6M | -$98.6M |
| Income tax | $491,000 | $55,000 | $7,000 | $70,000 | -$381,000 |
| Net income | -$146.9M | -$113.9M | -$72.7M | -$96.3M | -$97.8M |
| EPS (diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 |
| Operating cash flow | -$121.2M | -$104.5M | -$79.7M | -$55.7M | -$108.2M |
| Free cash flow | -$121.7M | -$106.8M | -$80.3M | -$56.4M | -$109.2M |
| Cash & equivalents | $194.2M | $32.5M | $141.4M | $209.2M | $77.3M |
| Total assets | $233.7M | $65.7M | $183.0M | $246.5M | $146.7M |
| Total liabilities | $64.9M | $38.3M | $42.8M | $52.1M | $47.4M |
| Shareholders' equity | $168.8M | $27.4M | $140.2M | $194.5M | $99.3M |
Source: SEC EDGAR filings · CIK 0001613780 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.